Literature DB >> 16908858

Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y.

Giovanna Tosi1, Elisabetta Pilotti, Lorenzo Mortara, Andrea De Lerma Barbaro, Claudio Casoli, Roberto S Accolla.   

Abstract

The master regulator of MHC-II gene transcription, class II transactivator (CIITA), acts as a potent inhibitor of human T cell leukemia virus type 2 (HTLV-2) replication by blocking the activity of the viral Tax-2 transactivator. Here, we show that this inhibitory effect takes place at the nuclear level and maps to the N-terminal 1-321 region of CIITA, where we identified a minimal domain, from positions 64-144, that is strictly required to suppress Tax-2 function. Furthermore, we show that Tax-2 specifically cooperates with cAMP response element binding protein-binding protein (CBP) and p300, but not with p300/CBP-associated factor, to enhance transcription from the viral promoter. This finding represents a unique difference with respect to Tax-1, which uses all three coactivators to transactivate the human T cell leukemia virus type 1 LTR. Direct sequestering of CBP or p300 is not the primary mechanism by which CIITA causes suppression of Tax-2. Interestingly, we found that the transcription factor nuclear factor Y, which interacts with CIITA to increase transcription of MHC-II genes, exerts a negative regulatory action on the Tax-2-mediated HTLV-2 LTR transactivation. Thus, CIITA may inhibit Tax-2 function, at least in part, through nuclear factor Y. These findings demonstrate the dual defensive role of CIITA against pathogens: it increases the antigen-presenting function for viral determinants and suppresses HTLV-2 replication in infected cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908858      PMCID: PMC1568938          DOI: 10.1073/pnas.0601589103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  72 in total

Review 1.  Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2.

Authors:  Gerold Feuer; Patrick L Green
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

Review 2.  Transcriptional and post-transcriptional gene regulation of HTLV-1.

Authors:  Fatah Kashanchi; John N Brady
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

Review 3.  Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis.

Authors:  Mitsuaki Yoshida
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

Review 4.  Deregulation of cell-signaling pathways in HTLV-1 infection.

Authors:  William W Hall; Masahiro Fujii
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

Review 5.  The epidemiology and disease outcomes of human T-lymphotropic virus type II.

Authors:  Diana F Roucoux; Edward L Murphy
Journal:  AIDS Rev       Date:  2004 Jul-Sep       Impact factor: 2.500

6.  Aberrant activation of the interleukin-2 autocrine loop through the nuclear factor of activated T cells by nonleukemogenic human T-cell leukemia virus type 2 but not by leukemogenic type 1 virus.

Authors:  Akiko Niinuma; Masaya Higuchi; Masahiko Takahashi; Masayasu Oie; Yuetsu Tanaka; Fumitake Gejyo; Nobuyuki Tanaka; Kazuo Sugamura; Li Xie; Patrick L Green; Masahiro Fujii
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  PCAF interacts with tax and stimulates tax transactivation in a histone acetyltransferase-independent manner.

Authors:  H Jiang; H Lu; R L Schiltz; C A Pise-Masison; V V Ogryzko; Y Nakatani; J N Brady
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

8.  GTP binding by class II transactivator: role in nuclear import.

Authors:  J A Harton; D E Cressman; K C Chin; C J Der; J P Ting
Journal:  Science       Date:  1999-08-27       Impact factor: 47.728

Review 9.  The molecular biology of the CCAAT-binding factor NF-Y.

Authors:  R Mantovani
Journal:  Gene       Date:  1999-10-18       Impact factor: 3.688

10.  The discovery of the first human retrovirus: HTLV-1 and HTLV-2.

Authors:  Robert C Gallo
Journal:  Retrovirology       Date:  2005-03-02       Impact factor: 4.602

View more
  14 in total

1.  Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication.

Authors:  Giovanna Tosi; Greta Forlani; Vibeke Andresen; Marco Turci; Umberto Bertazzoni; Genoveffa Franchini; Guido Poli; Roberto S Accolla
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

2.  The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-κB by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein.

Authors:  Greta Forlani; Rawan Abdallah; Roberto S Accolla; Giovanna Tosi
Journal:  J Virol       Date:  2016-01-20       Impact factor: 5.103

Review 3.  Intracellular localization and cellular factors interaction of HTLV-1 and HTLV-2 Tax proteins: similarities and functional differences.

Authors:  Umberto Bertazzoni; Marco Turci; Francesca Avesani; Gianfranco Di Gennaro; Carlo Bidoia; Maria Grazia Romanelli
Journal:  Viruses       Date:  2011-05-09       Impact factor: 5.818

4.  Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication.

Authors:  Chiara Orlandi; Greta Forlani; Giovanna Tosi; Roberto S Accolla
Journal:  J Transl Med       Date:  2011-07-07       Impact factor: 5.531

Review 5.  HTLV-1/-2 and HIV-1 co-infections: retroviral interference on host immune status.

Authors:  Elisabetta Pilotti; Maria V Bianchi; Andrea De Maria; Federica Bozzano; Maria G Romanelli; Umberto Bertazzoni; Claudio Casoli
Journal:  Front Microbiol       Date:  2013-12-23       Impact factor: 5.640

6.  The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells.

Authors:  Greta Forlani; Filippo Turrini; Silvia Ghezzi; Alessandra Tedeschi; Guido Poli; Roberto S Accolla; Giovanna Tosi
Journal:  J Transl Med       Date:  2016-04-18       Impact factor: 5.531

Review 7.  Tripartite Motif 22 and Class II Transactivator Restriction Factors: Unveiling Their Concerted Action against Retroviruses.

Authors:  Greta Forlani; Roberto S Accolla
Journal:  Front Immunol       Date:  2017-10-18       Impact factor: 7.561

8.  Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1.

Authors:  Greta Forlani; Giovanna Tosi; Filippo Turrini; Guido Poli; Elisa Vicenzi; Roberto S Accolla
Journal:  Front Immunol       Date:  2017-05-15       Impact factor: 7.561

9.  Comparison of the Genetic Organization, Expression Strategies and Oncogenic Potential of HTLV-1 and HTLV-2.

Authors:  Francesca Rende; Ilaria Cavallari; Maria Grazia Romanelli; Erica Diani; Umberto Bertazzoni; Vincenzo Ciminale
Journal:  Leuk Res Treatment       Date:  2011-12-29

10.  The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators.

Authors:  Greta Forlani; Rawan Abdallah; Roberto S Accolla; Giovanna Tosi
Journal:  Front Microbiol       Date:  2013-08-22       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.